AI Article Synopsis

  • After 4 years of hormone treatment, his PSA levels improved significantly, leading to a decision for salvage robot-assisted prostate surgery due to non-metastatic castration-resistant prostate cancer.
  • Post-surgery, the patient's PSA dropped to undetectable levels, allowing him to stop hormone therapy, and he remained free of cancer recurrence for 3 years.

Article Abstract

The patient was a 63-year-old man with biopsy Gleason score of 4+5 prostate cancer with an initial prostate specific antigen level of (PSA) 51.2ng/ml. On imaging examination, extracapsular invasion, rectal invasion, and pararectal lymph node metastasis were found (cT4N1M0). After 4 years of androgen deprivation therapy, PSA decreased to 0.631ng/ml, and then increased gradually to1.2ng/ml. Computed tomographic scan showed that the primary tumor had shrunk and lymph node metastasis had disappeared; so salvage robot-assisted resection of the prostate (RARP) was performed for non-metastatic castration-resistant prostate cancer (m0CRPC). Since PSA decreased to an undetactable level, hormone therapy was terminated at 1 year. The patient remained recurrence-free for 3 years after surgery. RARP may be effective for m0CRPC, enabling discontinuation of androgen deprivation therapy.

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_69_2_59DOI Listing

Publication Analysis

Top Keywords

lymph node
12
node metastasis
12
hormone therapy
8
prostate cancer
8
androgen deprivation
8
deprivation therapy
8
psa decreased
8
case m0crpc
4
m0crpc hormone
4
therapy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!